Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Ajesh B. Maharaj
Based on 10 articles published since 2010
(Why 10 articles?)
||||

Between 2010 and 2020, A. Maharaj wrote the following 10 articles about Psoriasis.
 
+ Citations + Abstracts
1 Review Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations. 2017

Maharaj, Ajesh B / Chandran, Vinod. ·a Department of Internal Medicine, Prince Mshiyeni Memorial Hospital, Nelson R Mandela School of Medicine , University of KwaZulu-Natal , Durban , South Africa. · b Department of Clinical Immunology and Rheumatology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands. · c Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute , University Health Network , Toronto , Canada. · d Division of Rheumatology, Department of Medicine , University of Toronto , Toronto , Canada. · e Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Canada. · f Institute of Medical Science , University of Toronto, Toronto Western Hospital , Toronto , Canada. ·Expert Rev Clin Immunol · Pubmed #27826996.

ABSTRACT: INTRODUCTION: Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided more options to clinicians managing PsA. The purpose of this review is to update the reader on treatment options for PsA using conventional synthetic disease modifying agents (csDMARDs) and novel therapies including tumour necrosis factor alpha inhibitors, interleukin 12/23 inhibitor (ustekinumab), the interleukin 17 antagonists including secukinumab, brodalumab, ixekizumab, and the phosphodiesterase-4 inhibitor, apremilast. Areas covered: We reviewed published articles on the treatment of PsA. Our main sources of data included treatment recommendations, registry studies, systematic literature reviews, major randomised controlled trials for more recently approved drugs, and abstracts from the American College of Rheumatology and EULAR meetings. Expert commentary: An overview of the evidence for the use of various pharmacotherapeutic agents for treatment of this heterogeneous disease was compiled. Treatment options for the various domains of PsA are also discussed.

2 Review Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy. 2016

Chandran, Vinod / Maharaj, Ajesh B. ·a Department of Medicine, and Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Ontario , Canada. · b Institute of Medical Science , University of Toronto , Toronto , Ontario , Canada. · c Krembil Research Institute , University Health Network , Toronto , Ontario , Canada. · d Department of Internal Medicine , Prince Mshiyeni Memorial Hospital, Nelson R Mandela School of Medicine, University of Kwazulu-Natal , Durban , South Africa. · e Department of Clinical Immunology and Rheumatology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands. ·Expert Rev Clin Immunol · Pubmed #26807494.

ABSTRACT: The management of psoriatic arthritis (PsA) and psoriasis has undergone major advancements over the last decade. This has been made possible, in part, due to the introduction of new therapies for their management, as well as global collaboration in the development of outcome measures and "treat- to- target" paradigms. In this review article, we discuss how disease activity is measured and the outcome measures that have been recently developed for the management of PsA. The importance of assessing the individual domains as well as global assessments both from the physician and patient perspective, and the development of composite measures are discussed. The newer PsA specific measures are expected to be more commonly used in clinical trials as well as clinical practice.

3 Review Unusual cause of limited elbow movement in a patient with psoriatic arthritis. 2014

Maharaj, Ajesh B / Chandran, Vinod. ·Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands, and Prince Mshiyeni Memorial Hospital, Department of Internal Medicine, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa; maharaja30@ukzn.ac.za. · Division of Rheumatology, University of Toronto, Staff Physician, Division of Rheumatology, Toronto Western Hospital, Toronto, Ontario, Canada. ·J Rheumatol · Pubmed #25452180.

ABSTRACT: -- No abstract --

4 Review Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. 2014

Ogdie, Alexis / Schwartzman, Sergio / Eder, Lihi / Maharaj, Ajesh B / Zisman, Devy / Raychaudhuri, Siba P / Reddy, Soumya M / Husni, Elaine. ·From the University of Pennsylvania, Philadelphia, Pennsylvania; Hospital for Special Surgery, New York, New York, USA; Toronto Western Hospital, Toronto, Ontario, Canada; Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa, and Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Carmel Medical Center, Faculty of Medicine, Technion, Haifa, Israel; Rheumatology, VA Sacramento Medical Center; Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, UC Davis, Davis, California; Division of Rheumatology, New York University School of Medicine, New York, New York; and the Cleveland Clinic, Cleveland, Ohio, USA.A. Ogdie, MD, MSCE, University of Pennsylvania; S. Schwartzman, MD, Hospital for Special Surgery; L. Eder, MD, PhD, Toronto Western Hospital; A.B. Maharaj, MB, BS, HDipIntMed(SA), FCP(SA), Nelson R. Mandela School of Medicine, University of KwaZulu Natal and Academic Medical Center, University of Amsterdam; D. Zisman, MD, Carmel Medical Center, Faculty of Medicine, Technion; S.P. Raychaudhuri, MD, Rheumatology, VA Sacramento Medical Center; Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, UC Davis; S.M. Reddy, MD, Division of Rheumatology, New York University School of Medicine; E. Husni, MD, MPH, Cleveland Clinic. ·J Rheumatol · Pubmed #25362717.

ABSTRACT: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis that can lead to decreased health-related quality of life and permanent joint damage leading to functional decline. In addition to joint and skin manifestations, both psoriasis and PsA are associated with numerous comorbidities and extraarticular/cutaneous manifestations, which may influence the physician's choice of therapy. The objectives of this review are (1) to identify comorbidities in patients with PsA based on the available evidence; (2) to examine the effects of these comorbidities or extraarticular/cutaneous manifestation on the management of patients with PsA as well as the selection of therapy; and (3) to highlight research needs around comorbidities and treatment paradigms. This review is part of a treatment recommendations update initiated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

5 Article International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings. 2020

Elmamoun, M / Eraso, M / Anderson, M / Maharaj, A / Coates, L / Chandran, Vinod / Anonymous4581055 / Abogamal, A / Adebajo, A O / Ajibade, A / Ayanlowo, O / Azevedo, V / Bautista-Molano, W / Carneiro, S / Goldenstein-Schainberg, C / Hernandez-Velasco, F / Ima-Edomwonyi, U / Lima, A / Medina-Rosas, J / Mody, G M / Narang, T / Ortega-Loayza, A G / Ranza, R / Sharma, A / Toloza, S / Vega-Espinoza, L / Vega-Hinojosa, O. ·Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada. · Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada. · Library and Information Services, University Health Network, Toronto, Canada. · Prince Mshiyeni Memorial Hospital, Durban, South Africa. · University of Oxford, Oxford, UK. · Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada. vinod.chandran@uhnresearch.ca. · Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada. vinod.chandran@uhnresearch.ca. · Institute of Medical Science, University of Toronto, Toronto, Canada. vinod.chandran@uhnresearch.ca. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. vinod.chandran@uhnresearch.ca. · Department of Medicine, Memorial University, St. John's, Canada. vinod.chandran@uhnresearch.ca. · Al-Azhar Faculty of Medicine Cairo, Nasr City, Egypt. · University of Sheffield UK, Western Bank, Sheffield, S10 2TN, UK. · Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun state, Nigeria. · College of Medicine, University of Lagos/Lagos University Teaching Hospital Nigeria, Ishaga Rd, Idi-Araba, Lagos, Nigeria. · Federal University of Parana, Curitiba, PR, Brazil. · University Hospital Fundación Santa Fe de Bogotá and School of Medicine Universidad Militar Nueva Granada, Bogota, Colombia. · State University of Rio de Janeiro and Federal University of Rio de Janeiro, Av. Pedro Calmon, 550 - Cidade Universitária da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-901, Brazil. · Disciplina de Reumatologia, LIM-17, Hospital das Clinicas HCFMUSP, Faculty of Medicine - University of Sao Paulo, Sao Paulo, SP, Brazil. · Fundación Universitaria Autónoma de las Américas, Pereira, Colombia. · Regional University of Blumenau (FURB), Blumenau, SC, Brazil. · Posthumous, University of Valle, University of La Sabana, Imbanaco Medical Center, Cali, Colombia. · University of KwaZulu-Natal, Durban, South Africa. · Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India. · Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd, Portland, USA. · Rheumatology Unit, Federal University of Uberlandia, Uberlândia, MG, Brazil. · Ministry of Health, Catamarca, Catamarca, Argentina. · Air Force Hospital, Lima, Peru. · Reumacenter Clinic, Puno, Peru. ·Clin Rheumatol · Pubmed #31950441.

ABSTRACT: BACKGROUND: Psoriatic arthritis (PsA) is a challenging heterogeneous disease. The European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) last published their respective recommendations for the management of PsA in 2015. However, these guidelines are primarily based on studies conducted in resource replete countries and may not be applicable in countries in the Americas (except Canada and USA) and Africa. We sought to adapt the existing recommendations for these regions under the auspices of the International League of Associations for Rheumatology (ILAR). PROCESS: The ADAPTE Collaboration (2009) process for guideline adaptation was followed to adapt the EULAR and GRAPPA PsA treatment recommendations for the Americas and Africa. The process was conducted in three recommended phases: set-up phase; adaptation phase (defining health questions, assessing source recommendations, drafting report), and finalization phase (external review, aftercare planning, and final production). RESULT: ILAR recommendations have been derived principally by adapting the GRAPPA recommendations, additionally, EULAR recommendations where appropriate and supplemented by expert opinion and literature from these regions. A paucity of data relevant to resource-poor settings was found in PsA management literature. CONCLUSION: The ILAR Treatment Recommendations for PsA intends to serve as reference for the management of PsA in the Americas and Africa. This paper illustrates the experience of an international working group in adapting existing recommendations to a resource-poor setting. It highlights the need to conduct research on the management of PsA in these regions as data are currently lacking.Key Points• The paper presents adapted recommendations for the management of psoriatic arthritis in resource-poor settings.• The ADAPTE process was used to adapt existing GRAPPA and EULAR recommendations by collaboration with practicing clinicians from the Americas and Africa.• The evidence from resource-poor settings to answer clinically relevant questions was scant or non-existent; hence, a research agenda is proposed.

6 Article MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis. 2018

Maharaj, Ajesh B / Naidoo, Pragalathan / Ghazi, Terisha / Abdul, Naeem S / Dhani, Shanel / Docrat, Taskeen F / Ramkaran, Prithiksha / Tak, Paul-Peter / de Vries, Niek / Chuturgoon, Anil A. ·Department of Internal Medicine, Prince Mshiyeni Memorial Hospital and School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. · Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. · School of Laboratory Medicine and Medical Sciences, Discipline of Medical Biochemistry and Chemical Pathology, University of KwaZulu-Natal, George Campbell Building - South Entrance, 3rd Floor, King George V Avenue, Howard College Campus, Durban, 4001, South Africa. · School of Laboratory Medicine and Medical Sciences, Discipline of Medical Biochemistry and Chemical Pathology, University of KwaZulu-Natal, George Campbell Building - South Entrance, 3rd Floor, King George V Avenue, Howard College Campus, Durban, 4001, South Africa. chutur@ukzn.ac.za. ·BMC Med Genet · Pubmed #29587639.

ABSTRACT: BACKGROUND: Psoriasis and psoriatic arthritis (PsA) are inflammatory associated autoimmune disorders. MicroRNA (miR)-146a plays a crucial role in regulating inflammation. A single nucleotide polymorphism in the miR-146a gene (rs2910164), aberrantly alters its gene expression and linked with the pathogenesis of several disorders, including psoriasis and PsA. In South Africa, psoriasis and PsA are extremely rare in the indigenous African population and most common in both the Indian and Caucasian population. The aim of this study was to investigate whether the miR-146a rs2910164 contributes towards psoriasis and PsA development in South African Indian and Caucasian patients. METHODS: South African Indian (n = 84) and Caucasian (n = 32) PsA patients (total n = 116) and healthy control subjects (Indian: n = 62 and Caucasian: n = 38; total n = 100) were recruited in the study. DNA was extracted from whole blood taken from all subjects, and genotyped for the miR-146a rs2910164 using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Data for laboratory parameters were obtained from pathology reports. The consulting rheumatologist collected all other clinical data. RESULTS: Unstratified data (Caucasians + Indians): A significant decrease in C-reactive protein (CRP) levels in PsA patients was observed (CRP monitored at inclusion vs. after 6 months of treatment) (18.95 ± 2.81 mg/L vs. 9.68 ± 1.32 mg/L, p = 0.0011). The miR-146a rs2910164 variant C-allele frequency in PsA patients was significantly higher vs. healthy controls (35.78% vs. 26% respectively, p = 0.0295, OR = 1.59 95% CI 1.05-2.40). Stratified data (Indians): The variant C-allele frequency in Indian PsA patients was significantly higher vs. healthy Indian controls (35.71% vs. 22.58%, p = 0.0200, OR = 1.91 95% CI 1.13-3.22). Stratified data (Caucasians): The variant C-allele frequency distribution between Caucasian PsA patients and healthy Caucasian controls was similar. CONCLUSION: The rs2910164 variant C-allele may play a role in the progression of PsA in the South African Indian population. The main limitation in this study was the small sample size in the case-control cohorts, with a low overall statistical power (post-hoc power analysis = 19%).

7 Article Summary of Sensitivity and Specificity for Psoriatic Arthritis in a South African Cohort according to Classification Criteria. 2015

Maharaj, Ajesh B / Govender, Jayandran / Maharaj, Kasthurba / Rajkaran, Michelle / Tak, Paul P. ·From the Department of Internal Medicine, Prince Mshiyeni Memorial Hospital, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa; and the Division of Clinical Immunology and Rheumatology, European League Against Rheumatism (EULAR) and Federation of Clinical Immunology Societies (FOCIS) Center of Excellence, Academic Medical Center/University of Amsterdam, University of Amsterdam, the Netherlands.A.B. Maharaj, MB, BS (Varanasi), H Dip Int Med(SA), FCP (SA), Certificate in Rheumatology (SA), Department of Internal Medicine, Prince Mshiyeni Memorial Hospital, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, and Division of Clinical Immunology and Rheumatology, EULAR and FOCIS Center of Excellence, Academic Medical Center/University of Amsterdam; J. Govender, BSc (Hons)(UDW), MB, ChB (Medunsa); K. Maharaj, MB, ChB (Natal), FCP (SA); M. Rajkaran, MBChB (Wits), FCP(SA), Department of Internal Medicine, Prince Mshiyeni Memorial Hospital, Nelson R. Mandela School of Medicine, University of KwaZulu Natal; P.P. Tak, MD, PhD (UvA), Division of Clinical Immunology and Rheumatology, EULAR and FOCIS Center of Excellence, Academic Medical Center/University of Amsterdam. ·J Rheumatol · Pubmed #25877500.

ABSTRACT: OBJECTIVE: To evaluate the sensitivity and specificity of the classification criteria for psoriatic arthritis (PsA) in a South African cohort. METHODS: Data from consecutive patients with PsA and other chronic inflammatory arthritides were collected prospectively. Subjects were classified according to the classification criteria. The sensitivity and specificity in each group of patients were compared with a clinical diagnosis made by a rheumatologist. RESULTS: The European Spondylarthropathy Study Group criteria exhibited the lowest sensitivity followed by the Moll and Wright criteria. The sensitivity and specificity of the ClASsification for Psoriatic ARthritis (CASPAR) criteria were 98.4% and 99.7%, respectively. CONCLUSION: The CASPAR criteria were evaluated in our cohort and they performed well.

8 Minor Drs. Maharaj and Chandran reply. 2015

Maharaj, Ajesh B / Chandran, Vinod. ·Department of Clinical Immunology and Rheumatology, Academic Medical center, University of Amsterdam, Amsterdam, the Netherlands; maharaja30@ukzn.ac.za. · Department of Medicine, Division of Rheumatology, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada. ·J Rheumatol · Pubmed #26034234.

ABSTRACT: -- No abstract --

9 Minor Pancytopenia in a patient with psoriatic arthritis treated with methotrexate and concomitant lithium. 2015

Maharaj, Ajesh B / Chandran, Vinod. ·Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands, and Prince Mshiyeni Memorial Hospital, Department of Internal Medicine, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa; maharaja30@ukzn.ac.za. · Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada. ·J Rheumatol · Pubmed #25729049.

ABSTRACT: -- No abstract --

10 Minor Spondyloarthritis in African blacks. 2015

Maharaj, Ajesh B / Tak, Paul P. ·Certificate in Rheumatology (SA), Prince Mshiyeni Memorial Hospital, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa, and the Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; maharaja30@ukzn.ac.za. · Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands. ·J Rheumatol · Pubmed #25554810.

ABSTRACT: -- No abstract --